[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612763":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":31,"responsibleParty":47,"collaborators":20,"id":50,"slug":20,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":20,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":20,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":20,"overallStatus":34,"whyStopped":20,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment group A","EXPERIMENTAL","Herombopag， initial dose 7.5 mg po qd d1-14",[13],"Drug: Herombopag Olamine Tablets",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Herombopag Olamine Tablets","Herombopag 7.5 mg po qd，d1-14",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Yinduo Zeng, MD","PRINCIPAL_INVESTIGATOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},"Tao Qin, MD","CONTACT","86-02034071337","qintao5471@163.com",[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Sun Yat-sen Memorial Hospital","RECRUITING","Guangzhou","Guangdong","510120","China",{"type":40,"coordinates":41},"Point",[42,43],113.25,23.11667,{"lat":43,"lon":42},[46],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},{"type":24,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Yinduo Zeng","chief physician","100612763",false,"NCT07257809","Herombopag Treated T-DM1 Induced Platelet Reduction","A Multicenter, Single-arm Exploratory Clinical Study Evaluating the Efficacy and Safety of T-DM1 in Patients With Breast Cancer Who Developed Thrombocytopenia.","Inclusion：\n\n* Age 18-75 years, any gender;\n* Pathologically diagnosed with breast cancer based on histological or cytological examination, and previously treated with neoadjuvant anti-HER-2 therapy followed by T-DM1 adjuvant therapy;\n* Experienced grade 2 or higher tumor treatment-related thrombocytopenia during the previous T-DM1 treatment cycle, with platelet count restored to ≥100 × 109\u002FL and ≤200 × 109\u002FL prior to the next treatment;\n* ECOG performance status score: 0-2;\n* Planned to undergo at least two additional treatment cycles including T-DM1 administration, with the dose of T-DM1 in the current cycle consistent with the previous cycle;\n* Expected survival of ≥12 weeks and able to tolerate the current treatment regimen for at least two cycles or more;\n* Expected to have good compliance, able to follow up on treatment efficacy and adverse reactions as required by the protocol.\n\nExclusion:\n\n* A history of other malignant tumors diagnosed within the past 3 years;\n* Patients with mental or neurological disorders who are unable to cooperate;\n* Patients who are scheduled to undergo or have previously undergone organ or bone marrow transplantation;\n* Patients with hematopoietic system disorders other than chemotherapy-induced thrombocytopenia (CTIT), including but not limited to leukemia, primary immune thrombocytopenia, myeloproliferative disorders, multiple myeloma, and myelodysplastic syndrome;\n* Patients with a history of any arterial or venous thrombotic events within the past 6 months prior to screening;\n* Severe bleeding manifestations within 2 weeks prior to screening, such as gastrointestinal or central nervous system bleeding;\n* Participation in a clinical trial of the same type of drug within 4 weeks prior to enrollment;\n* Pregnant or lactating women;\n* Patients with a history of hypersensitivity to the study drug;\n* Patients deemed ineligible by the investigator.","ALL","18 Years","75 Years",{"count":60,"type":61},56,"ESTIMATED","INTERVENTIONAL",[64],"PHASE2","This is a single-arm study planned to enroll 56 breast cancer patients who experienced grade 2 or higher thrombocytopenia following prior chemotherapy and achieved normalization (platelet count ≥100 × 109\u002FL and ≥200 × 109\u002FL) through intervention.",[67],"Thrombocytopenia","2025-11-27",{"date":70,"type":71},"2025-12-02","ACTUAL",{"date":73,"type":71},"2025-10-13",{"date":75,"type":61},"2027-09-26",{"name":5,"class":6},1]